United Therapeutics Corporation (UTHR)

Gross profit margin

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Gross profit (ttm)	US$ in thousands	2,567,700	2,451,400	2,324,900	2,220,200	2,070,000	1,961,900	1,901,400	1,806,200	1,787,600	1,732,600	1,670,800	1,642,900	1,563,000	1,532,500	1,471,600	1,398,400	1,375,200	1,307,400	1,319,800	1,330,600
Revenue (ttm)	US$ in thousands	2,877,400	2,756,200	2,616,700	2,498,300	2,327,500	2,204,300	2,110,900	1,981,300	1,936,300	1,860,000	1,788,700	1,768,300	1,685,500	1,655,200	1,590,600	1,506,100	1,483,300	1,409,500	1,430,900	1,442,500
Gross profit margin		89.24%	88.94%	88.85%	88.87%	88.94%	89.00%	90.08%	91.16%	92.32%	93.15%	93.41%	92.91%	92.73%	92.59%	92.52%	92.85%	92.71%	92.76%	92.24%	92.24%

December 31, 2024 calculation

Gross profit margin = Gross profit (ttm) ÷ Revenue (ttm)
= $2,567,700K ÷ $2,877,400K
= 89.24%

The gross profit margin of United Therapeutics Corporation has shown a generally high and stable trend over the past several quarters. Starting at 92.24% in March 2020 and staying consistently above 92% until June 2021, there was a slight increase to 93.41% in June 2022, indicating strong profitability. However, there was a gradual decline in the gross profit margin from there onwards. The margin dropped to 88.94% by December 2024, showing a decrease in the company's ability to generate profits from its core business activities. It is essential for United Therapeutics Corporation to closely monitor and potentially address factors affecting its gross profit margin to ensure sustainable financial performance in the future.